Alnylam Pharmaceuticals Inc. (ALNY)

68.93
NASDAQ : Health Technology
Prev Close 67.91
Day Low/High 68.05 / 69.63
52 Wk Low/High 60.27 / 124.22
Avg Volume 962.90K
Exchange NASDAQ
Shares Outstanding 106.54M
Market Cap 7.23B
EPS -7.60
P/E Ratio N/A
Div & Yield N.A. (N.A)
Alnylam To Webcast Presentations At Upcoming May Investor Conferences

Alnylam To Webcast Presentations At Upcoming May Investor Conferences

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the following conferences in May: Deutsche Bank...

Alnylam Reports 12-Month Clinical Data From Phase 2 Open Label Extension (OLE) Study Of Patisiran, An Investigational RNAi Therapeutic For Patients With Familial Amyloidotic Polyneuropathy (FAP)

Alnylam Reports 12-Month Clinical Data From Phase 2 Open Label Extension (OLE) Study Of Patisiran, An Investigational RNAi Therapeutic For Patients With Familial Amyloidotic Polyneuropathy (FAP)

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today initial 12-month clinical data from its ongoing Phase 2 open-label extension (OLE) study with patisiran, an...

New Lifetime High For Alnylam Pharmaceuticals (ALNY)

New Lifetime High For Alnylam Pharmaceuticals (ALNY)

Trade-Ideas LLC identified Alnylam Pharmaceuticals (ALNY) as a new lifetime high candidate

Alnylam And Collaborators Publish Pre-clinical Study Results In Nature Medicine On ALN-AT3, An Investigational RNAi Therapeutic Targeting Antithrombin (AT) For The Treatment Of Hemophilia And Rare Bleeding Disorders (RBD)

Alnylam And Collaborators Publish Pre-clinical Study Results In Nature Medicine On ALN-AT3, An Investigational RNAi Therapeutic Targeting Antithrombin (AT) For The Treatment Of Hemophilia And Rare Bleeding Disorders (RBD)

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today the publication in Nature Medicine of pre-clinical results with ALN-AT3, an investigational RNAi therapeutic...

Alnylam To Webcast Presentation At 14th Annual Needham Healthcare Conference

Alnylam To Webcast Presentation At 14th Annual Needham Healthcare Conference

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the 14 th Annual Needham Healthcare Conference on Wednesday, April...

Alnylam Pharmaceuticals (ALNY) Weak On High Volume

Alnylam Pharmaceuticals (ALNY) Weak On High Volume

Trade-Ideas LLC identified Alnylam Pharmaceuticals (ALNY) as a weak on high relative volume candidate

Alnylam Presents Results From Natural History Study Of Patients With Familial Amyloidotic Cardiomyopathy (FAC) And Presents Complete Results From Phase 2 Clinical Trial For Revusiran, An Investigational RNAi Therapeutic For The Treatment Of FAC

Alnylam Presents Results From Natural History Study Of Patients With Familial Amyloidotic Cardiomyopathy (FAC) And Presents Complete Results From Phase 2 Clinical Trial For Revusiran, An Investigational RNAi Therapeutic For The Treatment Of FAC

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today results from a retrospective natural history study evaluating disease progression in transthyretin (TTR)-mediated...

Alnylam To Webcast Presentation At 22nd Annual Future Leaders In The Biotech Industry Conference

Alnylam To Webcast Presentation At 22nd Annual Future Leaders In The Biotech Industry Conference

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the 22 nd Annual Future Leaders in the Biotech Industry Conference...

Alnylam To Webcast Presentation At Barclays Global Healthcare Conference

Alnylam To Webcast Presentation At Barclays Global Healthcare Conference

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the Barclays Global Healthcare Conference on Thursday, March 12, 2015...

Insiders Were Right: ALNY Makes New 52-Week High

Insiders Were Right: ALNY Makes New 52-Week High

In trading on Thursday, shares of Alnylam Pharmaceuticals Inc touched a new 52-week high of $115.43/share. That's a 145.44% rise, or $68.4 per share from the 52-week low of $47.03 set back on 04/28/2014.

Insider Trading Alert - ALNY, SCX And NSIT Traded By Insiders

Insider Trading Alert - ALNY, SCX And NSIT Traded By Insiders

Stocks with insider trader activity include ALNY, SCX and NSIT

Alnylam To Webcast Presentation At Cowen & Company 35th Annual Health Care Conference

Alnylam To Webcast Presentation At Cowen & Company 35th Annual Health Care Conference

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the Cowen and Company 35 th Annual Health Care Conference on...

Alnylam To Webcast Presentation At 2015 RBC Capital Markets' Global Healthcare Conference

Alnylam To Webcast Presentation At 2015 RBC Capital Markets' Global Healthcare Conference

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the 2015 RBC Capital Markets' Global Healthcare Conference on...

Trade-Ideas: Alnylam Pharmaceuticals (ALNY) Is Today's Post-Market Leader Stock

Trade-Ideas: Alnylam Pharmaceuticals (ALNY) Is Today's Post-Market Leader Stock

Trade-Ideas LLC identified Alnylam Pharmaceuticals (ALNY) as a post-market leader candidate

Alnylam Pharmaceuticals Reports Fourth Quarter And Full Year 2014 Financial Results And Highlights Recent Period Progress

Alnylam Pharmaceuticals Reports Fourth Quarter And Full Year 2014 Financial Results And Highlights Recent Period Progress

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today reported its consolidated financial results for the fourth quarter and full year 2014, and highlighted recent progress in...

Corporate Leaders Receive Fifteenth Annual Emerald Asset Management "E-3 Awards"

Corporate Leaders Receive Fifteenth Annual Emerald Asset Management "E-3 Awards"

The chief executive officers of Alnylam Pharmaceuticals (NASDAQ: ALNY), Apogee Enterprises (NASDAQ: APOG), Proofpoint, Inc.

Alnylam To Webcast Conference Call Discussing Fourth Quarter And Full Year 2014 Financial Results

Alnylam To Webcast Conference Call Discussing Fourth Quarter And Full Year 2014 Financial Results

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it will report financial results for the fourth quarter and year ending December 31, 2014 on Thursday, February...

5 Stocks Insiders Love Right Now: Microsoft, Alnylam and More

5 Stocks Insiders Love Right Now: Microsoft, Alnylam and More

Insiders at these companies have been scooping up shares of their own stock lately.

Alnylam To Webcast Presentation At Upcoming Investor Conferences

Alnylam To Webcast Presentation At Upcoming Investor Conferences

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the 17 th Annual BIO CEO & Investor Conference on Tuesday,...

U.S. Congressman Patrick Meehan To Present Keynote Address At 22nd Annual Groundhog Investment Forum

U.S. Congressman Patrick Meehan To Present Keynote Address At 22nd Annual Groundhog Investment Forum

Emerald Asset Management, Inc. has announced that U.

Alnylam Initiates Phase 1/2 Clinical Trial For ALN-CC5, A Subcutaneously Administered RNAi Therapeutic Targeting Complement Component C5 In Development For The Treatment Of Complement-Mediated Diseases

Alnylam Initiates Phase 1/2 Clinical Trial For ALN-CC5, A Subcutaneously Administered RNAi Therapeutic Targeting Complement Component C5 In Development For The Treatment Of Complement-Mediated Diseases

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, today announced that it has initiated a Phase 1/2 clinical trial with ALN-CC5, a subcutaneously administered investigational RNAi...

Investment Industry To Gather In Philadelphia At 22nd Annual Groundhog Day Investment Forum

Investment Industry To Gather In Philadelphia At 22nd Annual Groundhog Day Investment Forum

Emerald Asset Management, Inc. will welcome hundreds of investment industry professionals to the 22 nd annual Emerald Groundhog Day Investment Forum, scheduled to be held on Thursday, February 5 th at the Radisson Blu...

Alnylam Pharmaceuticals (ALNY) Moving On Heavy Pre-Market Trading

Alnylam Pharmaceuticals (ALNY) Moving On Heavy Pre-Market Trading

Trade-Ideas LLC identified Alnylam Pharmaceuticals (ALNY) as a pre-market mover with heavy volume candidate

Alnylam Pharmaceuticals Prices Public Offering Of Common Stock

Alnylam Pharmaceuticals Prices Public Offering Of Common Stock

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, today announced the pricing of an underwritten registered public offering of 4,736,842 shares of its common stock at a public offering price...

Alnylam Pharmaceuticals Announces Proposed Public Offering Of $450 Million Of Common Stock

Alnylam Pharmaceuticals Announces Proposed Public Offering Of $450 Million Of Common Stock

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, today announced that it has commenced an underwritten public offering of shares of its common stock to raise aggregate proceeds of...

Alnylam Reports Initial Evidence For Potential Correction Of The Hemophilia Phenotype In Phase 1 Study Of ALN-AT3, A Subcutaneously Administered, Investigational RNAi Therapeutic Targeting Antithrombin For The Treatment Of Hemophilia

Alnylam Reports Initial Evidence For Potential Correction Of The Hemophilia Phenotype In Phase 1 Study Of ALN-AT3, A Subcutaneously Administered, Investigational RNAi Therapeutic Targeting Antithrombin For The Treatment Of Hemophilia

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today updated results from its ongoing Phase 1 study of ALN-AT3, a subcutaneously administered, investigational RNAi...

(Photo Credit: Business Wire)

(Photo Credit: Business Wire)

Isis Pharmaceuticals, Inc. (Nasdaq:ISIS) and Alnylam Pharmaceuticals, Inc.

Alnylam Launches "Alnylam 2020" Guidance For Advancement And Commercialization Of RNAi Therapeutics

Alnylam Launches "Alnylam 2020" Guidance For Advancement And Commercialization Of RNAi Therapeutics

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today its "Alnylam 2020" guidance for the advancement and commercialization of RNAi therapeutics as a whole new class of...

Alnylam To Webcast Presentation At 33rd Annual J.P. Morgan Healthcare Conference

Alnylam To Webcast Presentation At 33rd Annual J.P. Morgan Healthcare Conference

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the 33 rd Annual J.

Alnylam Files Clinical Trial Application To Initiate A Phase 1 Study For ALN-AS1, A Subcutaneously Administered, Investigational RNAi Therapeutic Targeting Aminolevulinic Acid Synthase-1 (ALAS-1) For The Treatment Of Hepatic Porphyrias

Alnylam Files Clinical Trial Application To Initiate A Phase 1 Study For ALN-AS1, A Subcutaneously Administered, Investigational RNAi Therapeutic Targeting Aminolevulinic Acid Synthase-1 (ALAS-1) For The Treatment Of Hepatic Porphyrias

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today that it has filed a Clinical Trial Application (CTA) with the Swedish Medical Products Agency (MPA) to initiate a Phase...

TheStreet Quant Rating: D (Sell)